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Postmenopausal Bone loss: 

Prevention and Replacement. 

M. Brincat *, M. Meschia**, E. Barbacini**, P.G. Crosignani**, W. Albisetti ***, 
Clinical trial on efficacy of a 
combination of elcatonin 
(carbocalcitonin) and conjugated 
oestrogens in 
postmenopausal 
normal early 
woman. 
Summary 
Combination therapy of 
Carbocalcitonin (Elcatonin) and oral 
conjugated oestrogens (Premarin) 
not only prevents postmenopausal 
bone loss but leads to an increase in 
bone mass in normal early 
postmenopausal women. 
Introduction 
Osteoporosis is a skeletal disorder 
predominantly affecting 
postmenopausal women. 
The physiologically balanced 
coupling mechanism of bone 
formation and bone resorption 
ensures the skeleton's integrity and 
renewal. 
Peak bone mass is reached in the 
fourth decade of life. In the early 
postmenopausal years there is an 
accelerated bone loss. By the age of 
79 years a woman loses 50% of her 
bone mass while a man loses only 
25% by the age of 90 (1). It is 
estimated that by the age of 65 some 
40% of women would have 
experienced at least one osteoporotic 
fracture (2). This is due to a decline 
in bone organic matrix, the primary 
pathological event leading to 
osteoporosis (3). 
Oral oestrogen administration has 
been shown to arrest 
postmenopausal bone loss (4,5). 
However, it has been suggested that 
oestrogen treatment on its own win 
only reduce the risk of osteoporotic 
fractures by 50% (6). This is probably 
because therapy is started too late 
or bone mass at the start of the 
menopause in certain individuals 
lies within the low normal range. 
Calcitonin, like oestrogen, when 
used alone has also been shown to 
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Fig. 1. Changes in vertebral bane mass during one year's treatment with 
Premarin and Cakitonin compared to changes r.dth Cakitonin only. The 
significance levels shown indicate comparillon. with base line levels. 
prevent postmenopausal bone loss 
(7,8). 
Many treatment strategies have 
been developed in the management 
of postmenopausal bone loss aimed 
at maintaining bone mass. To date 
only limited work has been aimed at 
increasing bone mass. 
Aims 
The aims of the study was to 
investigate the effect of combination 
therapy on early postmenopausal 
bone loss. A combination of 
Elcatonin (Carbo calcitonin) and 
Premarin was compared to 
Premarin alone, and to Elcatonin 
(Carbocalcitonin) alone and all 
groups were then compared to a 
control group. 
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Elcatonin 
Calcitonin is an endogenous 32 ­
amino acid polypeptide hormone 
which binds to specific receptors on 
osteoclasts inhibiting bone 
resorption. 
Elcatonin (ISF) is a recently 
developed synthetic analogue of eel 
calcitonin with a greater stability to 
pH and temperature than other 
Calcitonins. Weight for weight 
Elcatonin is more biologically active 
than other calcitonins. Weight for 
weight Elcatonin is as biologically 
active as salmon and natural eel 
calcitonin. 
Patients and Methods 
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Fig. H. Changes in verlebral bone maBB during one year. treatment with 
Premarin and Calcitonin compared 10 changes with Premarin only. The 
Bignificwwe /eve,. shown indicaIe compariIIonB with baBe line /evel& 
The patients were randomly 
assigned to one of the following 
treatment groups: 
Group A 40 MRCU of Elcatonin (1 
ampoule) i.m. twice a week 
Group B 40 MRCU of Elcatonin (1 
ampoule) im. twice a week 
associated with conjugated 
oestrogens l.25mg dailyo:ally, plus 
medroxyprogesterone acetate lOmg 
daily 
orally for 10 days monthly. 
Group C Conjugated oestrogens 
l.25mg daily orally plus 
medroxyprogesterone acetate lOmg 
daily orally for 10 days monthly. 
Group D no. treatment 
All the patients were normal women 
who were at least 6 months and not 
more than 10 years postmenopausal. 
Table 1 gives the patient data. 
Patients were recruited if they had 
clinical evidence of the menopause 
supported by a high plasma level of 
Follicle- stimulating Hormone (FSH 
value > 40 lUll). 
Patients were excluded from 
entering the study if they had any of 
the following: 
- Therapy . with sex steroids during 
the year preceding the admission to 
the study 
severe hepatic, renal, cardiac or 
gastroenterologic disease 
inflammatory or degenerative 
osteomuscular diseases (Paget's 
disease, osteomalacia, rheumatoid 
arthritis) 
alcoholism 
metabolic disorders (e.g. diabetes 
mellitus) unless under stable 
medical control (none in fact were 
involved) 
neoplastic disease 
treatment with drugs affecting 
bone metabolism in the 4 weeks 
preceding the inclusion in the study 
Patients were assessed at baseline 
and after 3, 6 and 12 months on the 
study. The following information 
was obtained before randomisation 
to treatment: 
- Age 
- Years since the onset menopause 
- Follicle - stimulating hormone 
(FSH) serum levels 
- Bone density of lumbar spine (L2 
- IA) by Dual Beam Photon 
Absorptiometry CNorland) 
- Clinical ex&mination 
On the 3rd, 6h, and 12th month, a 
repeat assessment of the l'.ID1bar 
spine was carr.ed 01.>.1; using Dual 
Beam Phot.on Absorptiometry 
(Norland). 
This method was used to assess the 
bone density of L2 to IA. AlI'cases 
were assessed in a blind fashion by 
one of us (WN. The error in the 
method at the lumbar spine was 
calculated as being 1.5%. 
In this report we present the results 
of 44 patients who completed 1 year 
of follow up. (75 were originally 
admitted to the study and 
randomised to one of the treatment 
groups). 
The high rate of drop-outs (30%) is 
due to the long treatment duration 
and to the difficulties in getting full 
compliance from patients, especially 
since this involved a considerable 
amount of travelling. To our 
knowledge no patients have dropped 
out because of side effects, although 
some women on Calcitonin alone 
complained of flushes in the initial 
months of the study. 
Statistical Methods 
After testing for normality, 
statistical analysis was carried out 
using a paired Student's t-test. 
Across group comparisons at 0, 3, 6 
and 12 months were carried out 
using a one-way analysis of variance. 
Results 
The results of the study are shown 
in Figures 1, 2 and 3. 
The Premarin and Elcatonin group 
showed a significant mean increase 
in vertebral bone mass of 11.24% at 
the end of one year's therapy. 
The Premarin only group showed a 
non-significant mean increase of 
3.9% as did the Elcatonin only group
(2.3%) at the end of one year s 
therapy. 
The control group showed a 
significant mean bone loss of 4.8% 
after being followed up for one year. 
There was no statistical significance 
in bone mass between the groups at 
the start of the study. 
Table (2) gives a comparison of the 
results on the different regimens at 
the end of one year's therapy. 
Conclusion and Discussion 
The data for the patients who 
completed 12 months of treatment, 
CA) Confirms that vertebral bont': 
mass is lost rapidly in the initial 
postmenopausal years (1). 
CB) Confirms that this loss can be 
prevented by either Oestrogens 
alone C4,5) or Calcitonin alone (7,8). 
CC) Indicates that Oestrogens 
CPremarin) and Carbocalcitonin 
CElcatonin) combined in adequate 
doses, not only prevents early 
postmenopausal bone loss but results 
in a significant gain. In our study 
the mean gain was of 11.2% after 
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one year. The indications are that 
most of this gain occurs in the first 
6 months of therapy with levelling 
off then occurring. 
Although the clinical significance of 
such a gain in bone mass in the 
combined group in ear~ 
postmenopausal women stiIl needs 
to be assessed it would be logical to 
suggest the following !~men for 
women who are at a high risk of 
developing postmenopausal 
osteoporotic fractures:­
(A) Combined therapy of Premarinl 
Gestogens + Elcatonin for the first 
year of treatment. 
(B) Maintenance of the bone mass 
after that with eight Premarinl 
Gestogen combinations alone or 
Elcatonin alone, depending on the 
overall clinical picture of the woman 
concerned. 
This therapeutic regimen is 
currently being analysed in a 
separate study. 
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